^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BNT115
i
Other names: BNT115, W_ova1 vaccine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BioNTech
Drug class:
Immunostimulant
Related drugs:
over1year
OLIVIA: Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy (clinicaltrials.gov)
P1, N=8, Terminated, University Medical Center Groningen | Trial completion date: Dec 2023 --> Jun 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Jun 2023; Despite the extension of the original recruitment period, the target number of evaluable patients defined in the study protocol could not be reached and recruitment for the trial was stopped at that point of time.
Trial completion date • Trial termination • Trial primary completion date • Combination therapy
|
CD8 (cluster of differentiation 8)
|
BNT115
over2years
OLIVIA: Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy (clinicaltrials.gov)
P1, N=10, Active, not recruiting, University Medical Center Groningen | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy
|
CD8 (cluster of differentiation 8)
|
BNT115
Share via
